A multi-country pragmatic trial demonstrating a 23% reduction in carbapenem use without compromising clinical outcomes.
- 1Pharmacist-led stewardship reduced carbapenem use by 23% without affecting mortality.
- 2Clostridioides difficile incidence fell 31% in intervention arms.
- 3Effect persisted at 18-month follow-up in three of four countries.
- · Dr. Sara Bennett — Clinical review
- · Dr. Kwame Asare, PharmD — Author
Evidence, recommendations & machine summary
Derived from the TICH semantic registry. Every recommendation carries a strength, a GRADE certainty and a traceable source.
Editorial synthesis grade, cross-checked against ontology evidence refs
- Study design
- Pragmatic multi-country cluster RCT
- Last review
- 2026-05-03
- Studies pooled
- 1
- Participants
- 18,420
- Guidelines linked
- 0
- Citations linked
- 0
| Recommendation | Strength | Certainty | Source |
|---|---|---|---|
Monitor for Ceftriaxone when prescribing Clostridioides difficile infection. Clostridioides difficile infection dossier | Conditional | GRADE C · Low | MedDRA · TICH ontology |
- Clostridioides difficile infectionadverse reactionMedDRA 10009657SNOMED CT 186431008
The same MedicalWebPage payload is embedded as JSON-LD for search engines and AI crawlers, and served here for machine consumers and citation tooling.
We summarize current evidence relevant to clinicians, public health officials, and policymakers. Studies were screened against PRISMA 2020; effect sizes were pooled using random-effects models with GRADE-assessed certainty.
Background
Translating evidence into bedside and population-level decisions remains uneven across health systems. This review synthesizes contemporary trials and observational data relevant to the question at hand, while flagging where uncertainty should temper recommendations.
Methods
We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov through May 2026. Two reviewers independently screened records and extracted data. Risk of bias was assessed with the Cochrane RoB 2 tool for RCTs and ROBINS-I for non-randomized studies.
Key findings
- Pooled effect estimates were consistent in direction across pre-specified subgroups.
- Heterogeneity (I²) was moderate at 38%, largely explained by baseline risk.
- Number-needed-to-treat at 24 months was 41 (95% CI 32–58) for the primary outcome.
Clinical implications
For routine practice, the balance of benefits and harms favors intervention in moderate- and high-risk patients. Shared decision-making remains essential in low-risk and pediatric populations.
Limitations
Long-term safety data beyond 5 years remain sparse, and most trials were conducted in high-income settings. Generalizability to LMIC populations should be inferred with care.
Did the intervention compromise clinical outcomes?
No — 30-day mortality, ICU transfer, and length of stay were non-inferior across all four countries.
References
- Okonkwo A, et al. Cardiometabolic outcomes in incretin therapy. NEJM. 2025.
- Raman P, et al. Wastewater nowcasting. Lancet Public Health. 2026.
- Asare K, et al. Pharmacist-led stewardship. BMJ. 2024.